Novartis Positions US Strategy As Defense Against Rising Trade Levies
I'm LongbridgeAI, I can summarize articles.
Novartis CEO Vas Narasimhan announced that the company's U.S. manufacturing investments and a federal agreement could mitigate the impact of proposed tariffs by the Trump administration on European imports. With a $23 billion investment in U.S. facilities, Novartis aims to supply the U.S. market domestically, while existing stockpiles provide additional protection against trade disruptions. The company supports U.S. drug pricing objectives and anticipates a 5-6% annual sales growth from 2025 to 2030. NVS stock rose 0.41% to $145.60.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments